Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rina Li

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Blood Advances|January 17, 2024
Burden of employment loss and absenteeism in adults and caregivers of children with sickle cell diseaseRachel D'Amico Gordon, Rina Li Welkie, Nives Quaye, et al.
Current Issues in Molecular Biology|May 26, 2023
Hidradenitis Suppurativa: Molecular Etiology, Pathophysiology, and Management-A Systematic ReviewMichael Joseph Diaz, Shaliz Aflatooni, Parsa Abdi, et al.
Blood Advances|October 4, 2023
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort studyKaitlin Annunzio, Natalie S Grover, Rina Li Welkie, et al.
Cancers|March 11, 2023
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's LymphomaWalter Hanel, Polina Shindiapina, David A Bond, et al.
Journal of Hematology & Oncology|May 9, 2023
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite studyNarendranath Epperla, Rina Li Welkie, Pallawi Torka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AMLJoshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.
Blood Advances|February 3, 2026
Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML ReportJoshua F Zeidner, Jayanshu Jain, Rina Li Welkie, et al.
Haematologica|November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Cancer Journal|April 3, 2025
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trialFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Blood Advances|January 17, 2024
Burden of employment loss and absenteeism in adults and caregivers of children with sickle cell diseaseRachel D'Amico Gordon, Rina Li Welkie, Nives Quaye, et al.
Current Issues in Molecular Biology|May 26, 2023
Hidradenitis Suppurativa: Molecular Etiology, Pathophysiology, and Management-A Systematic ReviewMichael Joseph Diaz, Shaliz Aflatooni, Parsa Abdi, et al.
Blood Advances|October 4, 2023
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort studyKaitlin Annunzio, Natalie S Grover, Rina Li Welkie, et al.
Cancers|March 11, 2023
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's LymphomaWalter Hanel, Polina Shindiapina, David A Bond, et al.
Journal of Hematology & Oncology|May 9, 2023
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite studyNarendranath Epperla, Rina Li Welkie, Pallawi Torka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AMLJoshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.
Blood Advances|February 3, 2026
Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML ReportJoshua F Zeidner, Jayanshu Jain, Rina Li Welkie, et al.
Haematologica|November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Cancer Journal|April 3, 2025
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trialFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.
Pageof 3